Oxford, UK-based AI-powered medtech solutions company, Brainomix and Pixyl, France-based, an award-winning medtech firm specialising in medical neurology imaging, announced partnership to expand its offering with multiple sclerosis solutions. The company announced collaboration on November 25, 2022.
Purpose of the partnership between Brainomix and Pixyl
With the partnership between Brainomix and Pixyl, the former can distribute the latter’s Neuro.MS Software as a Service (SaaS) solution (SaaS). The solution aids in the diagnosis and treatment of patients with multiple sclerosis.
Besides, Brainomix aims to distribute exclusively in the UK as well as Ireland, the Nordics and key markets across Eastern Europe.
What the Brainomix official has to say
Dr Michalis Papadakis, Co-Founder and CEO of Brainomix, said, “We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions. We recognized that there was an opportunity to form these types of third-party technology partnerships as a way of offering our customers a broader set of AI-enabled solutions. We have achieved great success with our e-Stroke platform and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”
What the Pixyl founder has to say
Senan Doyle, Co-Founder and CEO of Pixyl, said, “Leveraging Brainomix’s large installed base and dedicated sales force in some of Europe’s leading markets represents a strategic step in our vision to broaden the adoption of AI-powered, clinically relevant solutions to drive better patient outcomes in the neurology imaging space.”
About Brainomix
In 2010, Founders Andrew Barker and Michalis Papadakis launched the company. Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer. The firm is a spin-out of the University of Oxford, United Kingdom. The company is an expanding commercial firm. Its award-winning imaging biomarkers and software solutions are popular in more than 30 countries worldwide.
e-Stroke platform, Brainbox’s first product, provides clinicians with the most comprehensive stroke imaging solution. It helps to drive faster treatment times and improve functional independence for patients. Its pipeline includes novel imaging biomarkers for better treatment of lung fibrosis and cancer. Moreover, pharmaceutical companies use the company’s technology to improve clinical trial success.
Boehringer Ingelheim Venture Fund, Parkwalk Advisors, Tencent Holdings and Oxford University Innovation Fund are the backers of the company.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
